Schott Pharma USA, a US-based subsidiary of German firm Schott Pharma, plans to build a new syringe production facility in the US state of North Carolina this year.
Schott Pharma will invest $371m in the project, located in Wilson. The facility will generate pre-fillable polymer and glass syringes for pharmaceutical and biotech companies, to help increase the U.S. supply of injectable vaccines and other therapeutic treatments, such as for diabetes.
Go deeper with GlobalData
Andreas Reisse, CEO Schott Pharma, said: “The impact of this facility will go far beyond local job creation in North Carolina and will relieve stress on the entire pharmaceutical industry supply chain.”
SCHOTT Pharma USA was enticed to Wilson County by almost $23m in incentives from state and local governments, including monetary, infrastructure, and training grants. An economic incentives committee is offering cash payments of nearly $5m, but they depend on the company meeting job-creation and investment thresholds.
SCHOTT Pharma employs over 4,600 workers worldwide. The facility is expected to commence operations in 2027.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
